Watch for the ESGCT late-breaking poster presentation (Oct 27-30) which will include 12-month Cohort 1 and interim Cohort 2 data — positive efficacy/safety signals could materially de-risk the BB-301. Final pivotal study design confirmation in Q1 2027 is the next binary catalyst.
Price Chart
Executive Summary
Benitec announced receipt of formal FDA feedback from a Type C meeting regarding the BB-301 pivotal study design. The FDA requested additional natural history data, pushing final study design confirmation to Q1 2027, but patient enrollment remains on track for mid-2027. Interim Phase 1b/2a data will be presented at ESGCT in late October 2026.
Key Facts
- FDA requested additional available data, including from the Benitec-sponsored OPMD Natural History Study, before finalizing the BB-301 pivotal study design
- Final pivotal study design expected to be confirmed in Q1 2027
- Patient enrollment for the BB-301 pivotal study remains on track to begin in mid-2027
- Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster at ESGCT Annual Congress, October 27-30, 2026, including 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients
- BB-301 has Orphan Drug Designation from EMA and Orphan Drug and Fast Track Designations from FDA
Financial Impact
No financial figures disclosed; regulatory milestone with no revenue or cash impact reported
Risk Factors
- FDA request for additional natural history data introduces modest timeline uncertainty before pivotal design is locked
- No approved OPMD therapies exist; BB-301 is still in Phase 1b/2a with no efficacy or safety data disclosed in this filing
- Clinical-stage biotech with no revenue and high cash burn — financing risk not addressed in this filing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-413177 |
| Document: bntc-ex99_1.htm | 0001193125-26-413177 |
| Document: 0001193125-26-413177-index-headers.html | 0001193125-26-413177 |
| Document: 0001193125-26-413177-index.html | 0001193125-26-413177 |
| Document: 0001193125-26-413177.txt | 0001193125-26-413177 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | DEFA14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.59 (+1.06%) |
Oct 20, 2026 6d ago | DEF 14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.59 (+1.06%) |
Oct 5, 2026 21d ago | 8-K | $9.23 $9.00 | ▼ −2.49% | ▼ −3.04% | $8.59 (−6.93%) |
Sep 30, 2026 26d ago | 8-K | $9.58 $8.98 | ▼ −6.26% | ▼ −7.00% | $8.59 (−10.33%) |
Sep 22, 2026 5w ago | EFFECT | $10.95 $9.83 | ▲ +10.23% | ▲ +9.51% | $8.59 (+21.55%) |
Sep 14, 2026 6w ago | Press Release | $11.05 $11.04 | ▼ −0.09% | ▲ +0.35% | $8.59 (−22.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.59 (−22.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.59 (−22.26%) |
May 14, 2026 23w ago | 8-K | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.59 (−27.51%) |
May 14, 2026 23w ago | Press Release | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.59 (−27.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers